SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 56,500 shares, an increase of 134.4% from the October 31st total of 24,100 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 29,800 shares, the short-interest ratio is presently 1.9 days.

SOPHiA GENETICS Stock Up 4.3 %

Shares of SOPH traded up $0.14 during mid-day trading on Friday, reaching $3.41. The company’s stock had a trading volume of 7,100 shares, compared to its average volume of 65,167. The company has a market cap of $222.95 million, a price-to-earnings ratio of -3.13 and a beta of 1.03. The business has a fifty day moving average of $3.50 and a 200 day moving average of $4.06. The company has a quick ratio of 3.59, a current ratio of 3.80 and a debt-to-equity ratio of 0.12. SOPHiA GENETICS has a 1 year low of $2.70 and a 1 year high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its earnings results on Tuesday, November 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The company had revenue of $15.85 million for the quarter, compared to analyst estimates of $15.90 million. During the same period last year, the business earned ($0.21) EPS. As a group, analysts forecast that SOPHiA GENETICS will post -0.98 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on SOPH shares. Royal Bank of Canada lowered their target price on SOPHiA GENETICS from $8.00 to $7.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Morgan Stanley lowered SOPHiA GENETICS from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $10.00 to $5.00 in a research report on Wednesday, August 7th.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of large investors have recently bought and sold shares of the business. Banque Cantonale Vaudoise boosted its holdings in SOPHiA GENETICS by 300.0% in the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after purchasing an additional 9,000 shares in the last quarter. Green Alpha Advisors LLC bought a new stake in SOPHiA GENETICS during the third quarter valued at about $79,000. Federated Hermes Inc. boosted its holdings in SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after acquiring an additional 23,000 shares during the period. Finally, Principal Financial Group Inc. boosted its holdings in SOPHiA GENETICS by 6.3% during the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after acquiring an additional 86,764 shares during the period. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.